The use of 5‐aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow‐up – an Epi‐IBD study

Autor: Ravi Misra, Riina Salupere, Renata D'Incà, Pia Oksanen, Elena Belousova, Jens Kjeldsen, Pekka Collin, Vicent Hernandez, Naila Arebi, Laszlo Lakatos, Luísa Castro, Selwyn Odes, Hendrika Al Kievit, Corinne Gower-Rousseau, Shaji Sebastian, Ebbe Langholz, Jóngerð Midjord, Adrian Goldis, I. Kaimakliotis, Doron Schwartz, Dimitrios K. Christodoulou, Konstantinos H. Katsanos, Zeljko Krznaric, Pierre Ellul, Pia Munkholm, Daniel Bergemalm, Johan Burisch, Kelly Gatt, Juozas Kupcinskas, Jonas Halfvarson, K R Nielsen, Dana Duricova, Vibeke Andersen, Karina Winther Andersen, M. Giannotta, Svetlana Turcan, Martin Bortlik, Gediminas Kiudelis, Mathurin Fumery, Jens Frederik Dahlerup, Peter L. Lakatos, Natalia Pedersen, Fernando Magro, Alessandro Sartini, V Domislović, D. Valpiani, Luísa Barros
Přispěvatelé: Örebro University, University Hospital Centre Zagreb, Partenaires INRAE, University of Zagreb, Victor Babeş University of Medicine and Pharmacy (UMFT), Aarhus University Hospital, Tampere University Hospital, University of Tampere [Finland], Complexo Hospitalario Universitario de Vigo, Université d'Etat de Médecine et Pharmacie, Chisinau, Republic of Moldova, Université d'Etat de Médecine et Pharmacie, Moscow Regional Research Clinical Institute (MONICA), Università degli Studi di Padova = University of Padua (Unipd), G.B. Morgagni-Pierantoni Hospital [Forlì, Italy], Azienda Usl Toscana centro [Firenze], Imperial College London, IBD clinical and research centre, ISCARE, Prague, Czech Republic, Charles University [Prague] (CU), Mater Dei Hospital [Malta], Odense University Hospital (OUH), University of Southern Denmark (SDU), University Hospital of Ioannina, University of Hull [United Kingdom], Centro Hospitalar Universitário de São João [Porto], Universidade do Porto = University of Porto, National Hospital of the Faroe Islands [Tórshavn, Faroe Islands], University of Tartu, Herning Hospital, Lithuanian University of health Sciences [Kaunas], CHU Amiens-Picardie, Service d'Epidémiologie et de Santé Publique [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Lille, Ben-Gurion University of the Negev (BGU), Semmelweis University [Budapest], McGill University Health Center [Montreal] (MUHC), University of Copenhagen = Københavns Universitet (UCPH)
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: United European Gastroenterol J
Burisch, J, Bergemalm, D, Halfvarson, J, Domislovic, V, Krznaric, Z, Goldis, A, Dahlerup, J F, Oksanen, P, Collin, P, de Castro, L, Hernandez, V, Turcan, S, Belousova, E, D'Incà, R, Sartini, A, Valpiani, D, Giannotta, M, Misra, R, Arebi, N, Duricova, D, Bortlik, M, Gatt, K, Ellul, P, Pedersen, N, Kjeldsen, J, Andersen, K W, Andersen, V, Katsanos, K H, Christodoulou, D K, Sebastian, S, Barros, L, Magro, F, Midjord, J M, Nielsen, K R, Salupere, R, Kievit, H A, Kiudelis, G, Kupčinskas, J, Fumery, M, Gower-Rousseau, C, Kaimakliotis, I P, Schwartz, D, Odes, S, Lakatos, L, Lakatos, P L, Langholz, E, Munkholm, P & Epi-IBD group 2020, ' The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up-an Epi-IBD study ', United European Gastroenterology Journal, vol. 8, no. 8, pp. 949-960 . https://doi.org/10.1177/2050640620945949
Burisch, J, Bergemalm, D, Halfvarson, J, Domislovic, V, Krznaric, Z, Goldis, A, Dahlerup, J F, Oksanen, P, Collin, P, de Castro, L, Hernandez, V, Turcan, S, Belousova, E, D'Incà, R, Sartini, A, Valpiani, D, Giannotta, M, Misra, R, Arebi, N, Duricova, D, Bortlik, M, Gatt, K, Ellul, P, Pedersen, N, Kjeldsen, J, Andersen, K W, Andersen, V, Katsanos, K H, Christodoulou, D K, Sebastian, S, Barros, L, Magro, F, Midjord, J M M, Nielsen, K R, Salupere, R, Kievit, H A L, Kiudelis, G, Kupčinskas, J, Fumery, M, Gower-Rousseau, C, Kaimakliotis, I P, Schwartz, D, Odes, S, Lakatos, L, Lakatos, P L, Langholz, E, Munkholm, P & for the Epi-IBD group 2020, ' The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up : an Epi-IBD study ', United European Gastroenterology Journal, vol. 8, no. 8, pp. 949-960 . https://doi.org/10.1177/2050640620945949
Burisch, J, Bergemalm, D, Halfvarson, J, Domislovic, V, Krznaric, Z, Goldis, A, Dahlerup, J F, Oksanen, P, Collin, P, de Castro, L, Hernandez, V, Turcan, S & for the Epi-IBD group 2020, ' The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study ', United European Gastroenterology Journal, vol. 8, no. 8, pp. 949-960 . https://doi.org/10.1177/2050640620945949
United European Gastroenterology Journal
United European Gastroenterology Journal, 2020, 8 (8), pp.949-960. ⟨10.1177/2050640620945949⟩
ISSN: 2050-6406
2050-6414
DOI: 10.1177/2050640620945949
Popis: BACKGROUND: The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn's disease is in sharp contrast to its widespread use in clinical practice.AIMS: The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn's disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease.METHODS: In a European community-based inception cohort, 488 patients with Crohn's disease were followed from the time of their diagnosis. Information on clinical data, demographics, disease activity, medical therapy and rates of surgery, cancers and deaths was collected prospectively. Patient management was left to the discretion of the treating gastroenterologists.RESULTS: Overall, 292 (60%) patients with Crohn's disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6-60). Of these, 78 (16%) patients received 5-aminosalicylate monotherapy during the first year following diagnosis. Patients who received monotherapy with 5-aminosalicylate experienced a mild disease course with only nine (12%) who required hospitalization, surgery, or developed stricturing or penetrating disease, and most never needed more intensive therapy. The remaining 214 patients were treated with 5-aminosalicylate as the first maintenance drug although most eventually needed to step up to other treatments including immunomodulators (75 (35%)), biological therapy (49 (23%)) or surgery (38 (18%)).CONCLUSION: In this European community-based inception cohort of unselected Crohn's disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn's disease, its use seems to result in a satisfying disease course for both patients and physicians.
Databáze: OpenAIRE
Externí odkaz: